provide an alternative mode of therapy, 2 particularly when long-term therapy is required, e.g. in the presence of prosthetic material.
Rifampicin, fusidic acid, and ciprofloxacin are the only widely available oral agents that have demonstrated consistent in-vitro activity in Australia 3, 4 and have been recommended in the therapy of MRSA infections. 5 In addition to the advantages of oral administration, these agents also demonstrate better tissue penetration than the glycopeptide agents. Resistance may occur to one or more of the oral agents, hence susceptibility must be demonstrated by in-vitro testing before clinical use of these agents can be considered. Combination therapy with two oral agents is thought to be important to decrease the risk of selecting for resistant mutants during therapy of MRSA infection. 2, 6, 7 Hence existing resistance to two or more of these oral agents practically excludes oral therapy from consideration. A significant prevalence of resistance to combinations of oral agents among MRSA would result in the greater and more prolonged use of glycopeptides, with the attendant problems of toxicity, complications of long-term intravenous lines, and increasing pressure for development of glycopeptide resistance, as recently documented for enterococci 1 and staphylococci. 8 This paper presents data from an ongoing prevalence study of resistance in S. aureus isolated from significant clinical specimens. 4, 9 The study involves 20 metropolitan teaching hospitals in eight major Australian cities. We believe this is the largest continuous surveillance study documenting staphylococcal resistance.
Materials and methods
These have been described in detail elsewhere. 4 Twenty teaching hospital laboratories in eight Australian cities (Brisbane, Sydney, Melbourne, Hobart, Canberra, Adelaide, Perth, and Darwin) participated in the study. Surveys were conducted each November from 1990 to 1995; each laboratory contributed 100 consecutive S. aureus isolates during that period. All isolates were from clinically infected sites. Duplicate isolates from the same patient and isolates collected for surveillance purposes were excluded. S. aureus was identified by positive results from at least two of: tube coagulase, slide coagulase, DNase, and latex agglutination test. Susceptibility testing was performed by agar dilution according to the recommendations of the National Committee for Clinical Laboratory Standards, 10 except between 1990 and 1992, when Isosensitest agar (Oxoid, West Heidelberg, Australia) was used with the addition of 5% horse blood. Antibiotic breakpoints were 1.0 mg/L for each of rifampicin, fusidic acid, and ciprofloxacin.
As part of the study, all MRSA isolates were submitted for phage typing, which was performed at the Royal Prince Alfred Hospital, Sydney, using both the Basic International Set of Typing Phages and an experimental set of phages as previously described.
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Results
Prevalence of MRSA (1990 MRSA ( -1995 From 1990 to 1995, 9997 isolates of S. aureus were tested from the Australian study sites (including university teaching hospitals in all capital cities), of which 1627 (16.3%) were resistant to methicillin. The percentage of isolates tested that were MRSA is shown in Figure 1 for each Australian capital city except Darwin. (1990-1995). 1990; 1991; 1992; 1993; 1994; 1995. Prevalence of oral drug resistance in eastern Australian MRSA isolates (1990 -1995 As sufficient numbers of MRSA isolates for valid comparison were available from only Sydney, Melbourne, and Brisbane, analysis of oral drug resistance was confined to isolates from these three cities. The changes in yearly prevalence of resistance to ciprofloxacin, rifampicin, and fusidic acid in the 1467 MRSA isolates collected from hospitals in these cities between 1990 and 1995 are shown in Figure 2 .
Over the survey period, the prevalence of MRSA strains demonstrating resistance to two or more of the three oral agents steadily rose (from 13.4% to 70.0%) in Brisbane, where almost all were ciprofloxacin/rifampicin resistant, and in Sydney (from 0 to 23.5%), where in 1995 half were ciprofloxacin/rifampicin resistant and half ciprofloxacin/fusidic acid resistant ( Figure 3 ). In 1990; 1991; 1992; 1993; 1994; 1995. Melbourne in 1995, despite higher endemic MRSA rates in the testing hospitals (up to 50% of all S. aureus), only one strain (0.8%) resistant to two oral agents was isolated. Resistance to all three agents has remained rare, with only seven such strains isolated over the six surveys.
Prevalence of oral drug resistance in eastern Australian hospitals in 1995
Resistance rates to ciprofloxacin, rifampicin, and fusidic acid in 311 MRSA isolates collected in 1995 from 11 individual metropolitan hospitals in Sydney, Melbourne, and Brisbane are shown in Table I .
Phage typing
Within cities and institutions, there was great diversity of phage type patterns for methicillin-resistant strains and, in parallel with this, for ciprofloxacin-resistant strains. Phage typing results were specifically compared for any known rifampicin-resistant isolates that were referred to the typing centre following the 1994 and 1995 studies (Table  II) . Six hospitals had supplied isolates. Of 47 isolates (26 in 1994 and 21 in 1995), 12 unique phage typing patterns were observed. Shared phage types were, in general, noted between institutions in the same city, suggesting crossinfection or transfer, but were uncommon between cities. In the two Brisbane institutions, 19 of 22 (86%) and 9 of 
Discussion
MRSA has been endemic in Australian hospitals for 15 years. As shown in Figure 1 , the prevalence of MRSA within cities has remained fairly constant over time, with relatively high prevalence ( 15% of S. aureus isolates) in the three main eastern seaboard cities (Sydney, Melbourne, Brisbane) and lower prevalence ( 10% of S. aureus isolates) in the other cities. In the past decade, Australian MRSA strains have been largely hospital acquired. As documented previously by the Australian Group for Antimicrobial Resistance (AGAR), 4,9 these strains have exhibited predictable resistance patterns, characterized by multiple resistance to gentamicin, erythromycin, clindamycin, tetracycline, and trimethoprim. Before 1990 most nosocomial or 'eastern Australian' (EA-MRSA) isolates tested were susceptible to ciprofloxacin, rifampicin, and fusidic acid; these, used in dual combination, have been the preferred choice for the oral management of MRSA infection. 5 Since 1990, however, despite a similar overall prevalence of MRSA, significant divergence in rates of resistance to ciprofloxacin, rifampicin, and fusidic acid has been noted between the three main cities of the eastern seaboard.
Ciprofloxacin was licensed for clinical use in Australia in 1988. It was seen at that time as a useful addition to the armamentarium of oral drugs available for the therapy of staphylococcal, especially MRSA, infection. However, significant ciprofloxacin resistance in MRSA developed rapidly worldwide, [12] [13] [14] [15] [16] even when used in combination with rifampicin. 17 Whereas rifampicin resistance disappeared when the selective pressure was reduced, quinolone resistance was more stable and ciprofloxacin-resistant strains persisted. In Australia, marketing data (Bayer Pharmaceuticals, personal communication) suggest that ciprofloxacin use has not differed between states, there being an early and rapid rise in clinical use following licensing. As a result, ciprofloxacin resistance in MRSA developed rapidly within four years of the introduction of the antibiotic and has remained at high levels since then. 4 In the New South Wales survey hospitals, ciprofloxacin resistance gradually climbed from 18.5% in 1990 to 95% in 1995. Retail figures indicate that between 1990 and 1995, there was 10-to 20-fold greater use of fluoroquinolones (ciprofloxacin and norfloxacin) in the Australian hospital sector and 100-fold greater use in the community sector (Bayer Pharmaceuticals, personal comm u n i c a t i o n ), when compared with the rise in quinolone use, rifampicin and fusidic acid use had remained relatively stable. Resistance development may thus reflect the greater volume of fluoroquinolone use, mostly as monotherapy, for nonstaphylococcal indications. Scheel et al., 18 in a longitudinal study in Hong Kong spanning 5 years (1988-1993) , documented ciprofloxacin resistance rising from 9% to 83% and associated with a great diversity of phage types. As in our survey, ciprofloxacin resistance could not be accounted for by proliferation of a single or dominant epidemic clone.
Ciprofloxacin resistance has developed at a different rate in each of the three eastern Australian cities. In the 1995 survey, ciprofloxacin resistance rates were lower in Melbourne (~16-24%) than in either Sydney (80-100%) or Brisbane (30-44%). Antibiotic use by itself does not explain the much sharper rise in quinolone resistance in Sydney. Hence the development of resistance is probably multifactorial, and local epidemiology and specific epidemic clone prevalence may contribute. By contrast, ciprofloxacin resistance in methicillin-sensitive S. aureus (MSSA) is only 2.4% nationwide, 4 indicating that other intrinsic factors must affect to the greater acquisition rate of quinolone resistance by MRSA strains.
Between 1990 and 1995 community use of rifampicin and fusidic acid (unlike ciprofloxacin) was restricted in Australia and most use has been in the hospital sector. While the prevalence of rifampicin resistance has remained stable in each of the three cities, rifampicin resistance was consistently higher in Brisbane (30-60%) than in Melbourne (5-10%) and Sydney ( 25%). In Brisbane and Sydney most rifampicin-resistant MRSA isolates were also resistant to ciprofloxacin. In Sydney, rifampicin resistance was first noted in 1992 and at that time was largely due to a focal outbreak of a single epidemic MRSA strain with a characteristic antibiogram (rifampicin-and ciprofloxacin-resistant but tetracycline susceptible). This strain rapidly spread through the implicated hospital, but has gradually waned since. 19 Genotyping (RFLP) has confirmed that these isolates were genetically related. 20 Phage typing from the current survey has demonstrated that this isolate had spread to at least one other Sydney hospital but it has not been recognized in the other cities. Indeed, phage typing has suggested that both Sydney and Brisbane have dominant circulating rifampicin-resistant phage types. In Brisbane this strain has become the established MRSA phage type in both major hospitals, which presumably accounts for the high rate of combined ciprofloxacin and rifampicin resistance seen since 1990. Hence, unlike ciprofloxacin resistance, rifampicin resistance in the two cities has been largely associated with the spread of specific strains. Rifampicin resistance remains extremely rare in MSSA. 4 Fusidic acid resistance was uncommon in all three cities ( 5%). This is consistent with previous reports that resistance to this agent is less likely to develop after acute clinical use, 6, 21 though in these studies oral fusidic acid was invariably used in combination. In the UK since 1989, fusidic acid resistance has remained stable at about 2% of all bloodstream S. aureus isolates. 22 Until recently, fusidic acid has not been widely available in Australia outside public hospitals and almost always it has been used in combination therapy, usually with rifampicin. It will be important to monitor for evidence of increasing resistance to fusidic acid as single-agent community use of oral and topical preparations increases.
The increased resistance noted from Sydney in 1994-1995 was largely due to an outbreak MRSA strain from a single hospital (accounting for 31% of all MRSA isolates). All isolates were of phage type 84/90/88/56A/ 90A/1648/87M/13M and were resistant to both ciprofloxacin and fusidic acid but susceptible to rifampicin. This outbreak aside, fusidic acid resistance rates in MRSA did vary greatly between cities, and resistance rates for MSSA and MRSA were similar, unlike the situation for ciprofloxacin and rifampicin.
Our survey results suggest that MRSA epidemiology is highly complex. Over the 5 years surveyed, resistance to ciprofloxacin has steadily increased, while resistance to rifampicin and fusidic acid has fluctuated in the centres with higher MRSA prevalence. In some institutions MRSA endemicity is due to diverse strains whereas in others a particular strain may predominate. The former scenario is more characteristic of ciprofloxacin resistance, especially in institutions where the majority of isolates are now quinolone resistant; rifampicin resistance conversely may correlate better with the establishment of an epidemic clone. Fusidic acid resistance remains largely sporadic, but clonal outbreaks are being recognized. Institutional strategies will continue to rely on effective infection control measures aimed at restricting antibiotic use and preventing cross-infection, particularly with oral-drugresistant MRSA strains. More attention should be paid to the potential for transfer of these strains between linked institutions. We conclude that, due to the increasing rates of resistance to the oral agents, reliance on parenteral anti-MRSA antibiotics is likely to continue.
